Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Health Care

60.10
+1.763.01%
Post-market: 60.100.00000.00%16:18 EDT
Volume:9K
Turnover:529.71K
Market Cap:95.56M
PE:- -
High:60.30
Open:59.41
Low:59.41
Close:58.34
52wk High:64.60
52wk Low:42.76
Shares:1.59M
Float Shares:1.59M
Volume Ratio:1.13
T/O Rate:0.55%
Dividend:0.63
Dividend Rate:1.05%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

UnitedHealth, Amazon.Com Inc. Share Gains Contribute to Dow's 138-Point Jump

Dow Jones
·
Oct 09

Abbvie Inc. : UBS Raises Target Price to $275 from $260

THOMSON REUTERS
·
Oct 09

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Oct 09

Merck & Company (MRK) Receives a Buy from UBS

TIPRANKS
·
Oct 09

UnitedHealth price target lowered to $402 from $430 at TD Cowen

TIPRANKS
·
Oct 09

U.S. Stocks on the MOVE-SpaceX, Humana, Delta Air Lines

Reuters
·
Oct 09

Piper Sandler recommends buying UnitedHealth on 2027 Star Ratings release

TIPRANKS
·
Oct 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 09

Johnson & Johnson reports new two-year results from Phase 3 ICONIC-LEAD study

TIPRANKS
·
Oct 09

J&J Says Phase 3 Iconic-LEAD Trial Shows Icotyde Sustains Plaque Psoriasis Clearance Through 2 Years

Reuters
·
Oct 09

J&J - at Week 112, 72% Achieve Pasi 90, 70% Achieve Iga 0/1 with Icotyde

THOMSON REUTERS
·
Oct 09

J&J - no New Safety Signals Identified for Icotyde Through Week 112

THOMSON REUTERS
·
Oct 09

New Johnson & Johnson Icotyde® (Icotrokinra) Long-Term Data Demonstrate Robust 2-Year Results in the Treatment of Adults and Adolescents with Plaque Psoriasis

THOMSON REUTERS
·
Oct 09

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Oct 09

Merck price target lowered to $163 from $166 at BofA

TIPRANKS
·
Oct 09

Lilly Says Phase 3b Together-PsO Data Show Broader Biomarker Shifts with Taltz Plus Zepbound vs Taltz Alone

Reuters
·
Oct 09

Eli Lilly price target lowered to $1,341 from $1,344 at BofA

TIPRANKS
·
Oct 09

Eli Lilly - Taltz and Zepbound Together Show Greater Reductions in Inflammatory Immune Activity

THOMSON REUTERS
·
Oct 09

Eli Lilly: Improvements were Maintained or Further Improved Through Week 52, with Safety Consistent with Known Profile of Each Respective Medicine

THOMSON REUTERS
·
Oct 09

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Advance Understanding of the Interconnected Immune and Metabolic Biology in Adults with Psoriasis and Obesity

THOMSON REUTERS
·
Oct 09